World Investment Advisors LLC Invests $3.46 Million in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

World Investment Advisors LLC acquired a new stake in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) in the third quarter, HoldingsChannel.com reports. The firm acquired 43,539 shares of the company’s stock, valued at approximately $3,459,000.

Other institutional investors also recently bought and sold shares of the company. Renaissance Technologies LLC increased its position in shares of Dr. Reddy’s Laboratories by 3.4% during the 2nd quarter. Renaissance Technologies LLC now owns 1,995,495 shares of the company’s stock valued at $152,037,000 after purchasing an additional 65,606 shares during the last quarter. Dimensional Fund Advisors LP grew its position in Dr. Reddy’s Laboratories by 12.8% during the second quarter. Dimensional Fund Advisors LP now owns 1,003,782 shares of the company’s stock valued at $76,455,000 after buying an additional 114,294 shares during the period. State Street Corp increased its holdings in Dr. Reddy’s Laboratories by 1.9% during the third quarter. State Street Corp now owns 909,905 shares of the company’s stock valued at $72,292,000 after buying an additional 16,641 shares during the last quarter. Fisher Asset Management LLC raised its position in Dr. Reddy’s Laboratories by 59.4% in the third quarter. Fisher Asset Management LLC now owns 491,303 shares of the company’s stock worth $39,034,000 after acquiring an additional 183,146 shares during the period. Finally, BNP Paribas Financial Markets boosted its stake in shares of Dr. Reddy’s Laboratories by 30.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 409,440 shares of the company’s stock worth $32,530,000 after acquiring an additional 96,339 shares during the last quarter. Institutional investors own 3.85% of the company’s stock.

Dr. Reddy’s Laboratories Price Performance

Shares of NYSE:RDY opened at $14.46 on Friday. The firm’s 50 day simple moving average is $14.88 and its two-hundred day simple moving average is $15.36. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.92 and a quick ratio of 1.36. The company has a market capitalization of $12.07 billion, a P/E ratio of 23.10 and a beta of 0.53. Dr. Reddy’s Laboratories Limited has a 1-year low of $13.26 and a 1-year high of $16.89.

Analysts Set New Price Targets

Several equities research analysts have recently commented on RDY shares. StockNews.com cut Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a report on Friday, December 6th. Barclays decreased their price objective on Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 6th.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.